Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

(Quarter Ended September 30, 2025)

1. Completed a streamlined Nasdaq listing, with a 100% common stock capital structure
2. Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations.
3. Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials.
4. Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies.
5. Launched AI strategy with the acquisition of MIT startup Oculo

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc., (“Vyome”) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US–India innovation corridor, today announced its financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq.

This quarter marks Vyome’s first full reporting period as a newly listed Nasdaq company. Vyome is a clinical-stage, and AI-focused company positioned to accelerate development across immuno-inflammatory and potential orphan indications.

“Vyome is targeting one of the biggest challenges in the world today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure, the development of our assets, or looking at AI opportunities,” said Krishna Gupta, Chairman of Vyome. “We had a great first quarter as a public company thanks to our unique strengths, including expertise in/access to the US-India innovation corridor. We announced an important interim result for our drug targeting the billion-dollar opportunity in malignant fungating wound (MFW), and it’s just the beginning!”

“This quarter marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in our first quarter as a public company and strengthening our organization while advancing our lead program,” noted Venkat Nelabhotla, CEO of Vyome. He further added, “The promising interim Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients.”

VT-1953: Highly Encouraging Interim Phase 2 study Readouts

The lead program, VT-1953, a topical agent targeting symptoms of putrid smell and pain in malignant fungating wounds (MFW), an inflammatory condition afflicting an estimated one million cancer patients, continued to show strong clinical momentum.

• Interim Phase 2 Investigator-Initiated Study data demonstrated statistically significant reductions in malodor (P